Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT)

$8.27 ▼ -0.36 (-4.18%)

As of May 12, 2026 12:10 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001768224

Market Cap 236.75 Mn

P/E -3.60

P/S 2.89

Div. Yield 0.00

Revenue Growth (1y) (Qtr) -68.39

Add ratio to table...

About

Arcturus Therapeutics Holdings Inc. is a messenger RNA medicines company focused on developing liver and respiratory rare disease therapeutics and infectious disease vaccines. It operates in the biotechnology industry within the mRNA therapeutic and vaccine sector. The company generates revenue primarily through collaboration agreements, upfront payments, milestone payments, profit sharing, royalties and product sales. Its main collaborative partner is CSL Seqirus for COVID 19, influenza and other infectious disease vaccines. It also receives funding...

Investment thesis

Bull case

Arcturus’ CF program leverages a unique inhaled sa‑mRNA platform that has shown early safety and meaningful mucus plug reduction in a small, class‑I cohort. This objective, imaging‑based biomarker signals that the therapy may alter disease biology, potentially translating into functional lung improvements once tested in a larger, longer study. The fact that the drug product is self‑amplifying means a single inhalation could sustain therapeutic protein levels, reducing dosing burden and supporting compliance. These properties together create a compelling opportunity for the first inhaled mRNA therapy to address an unmet need in cystic fibrosis.
Beyond CF, the company’s LUNAR lipid delivery system underpins a diverse pipeline that includes an OTC deficiency mRNA therapy and a spectrum of viral vaccines, from COVID‑19 to influenza. This breadth allows the organization to target multiple rare disease and infectious disease markets, diversifying revenue streams and mitigating concentration risk. Each therapeutic area benefits from the same core technology, which can accelerate development timelines and lower per‑product costs. The multi‑product platform therefore positions Arcturus to capture growth across several high‑impact therapeutic domains.
Arcturus holds an extensive intellectual‑property portfolio, with over 500 patents spanning lipid formulations, sa‑mRNA design, and manufacturing processes. Such depth creates a robust moat, limiting direct competition from entrants who would need to invest heavily to overcome these barriers. The breadth of patents also facilitates strategic licensing to other manufacturers, generating non‑recurring revenues and reinforcing the company’s market position. A strong IP position is therefore a core pillar of long‑term value creation.
The partnership with CSL Seqirus and the joint venture in Japan, ARCALIS, provide access to established manufacturing facilities and distribution networks for both vaccines and therapeutics. These collaborations reduce capital intensity and accelerate time‑to‑market for new products, while also sharing commercial risks. The joint venture’s presence in Japan ensures that regulatory approval pathways in a large and lucrative market are more readily navigated. Together, these alliances create synergies that can accelerate revenue generation and broaden global reach.
While revenue has declined, the company’s cash balance of $237 million at year‑end, coupled with disciplined cost reductions, extends the runway into 2028 under current burn assumptions. This extended runway provides the financial flexibility to fund late‑stage clinical trials and scale‑up manufacturing without immediate dilution or debt. It also gives management breathing space to negotiate further collaborations or secure follow‑on funding. A solid cash position thus mitigates the risk of a funding crunch that could otherwise derail the pipeline.

Arcturus’ CF program leverages a unique inhaled sa‑mRNA platform that has shown early safety and meaningful mucus plug reduction in a small, class‑I cohort. This objective, imaging‑based biomarker signals that the therapy may alter disease biology, potentially translating into functional lung improvements once tested in a larger, longer study. The fact that the drug product is self‑amplifying means a single inhalation could sustain therapeutic protein levels, reducing dosing burden and supporting compliance. These properties together create a compelling opportunity for the first inhaled mRNA therapy to address an unmet need in cystic fibrosis.
Beyond CF, the company’s LUNAR lipid delivery system underpins a diverse pipeline that includes an OTC deficiency mRNA therapy and a spectrum of viral vaccines, from COVID‑19 to influenza. This breadth allows the organization to target multiple rare disease and infectious disease markets, diversifying revenue streams and mitigating concentration risk. Each therapeutic area benefits from the same core technology, which can accelerate development timelines and lower per‑product costs. The multi‑product platform therefore positions Arcturus to capture growth across several high‑impact therapeutic domains.
Arcturus holds an extensive intellectual‑property portfolio, with over 500 patents spanning lipid formulations, sa‑mRNA design, and manufacturing processes. Such depth creates a robust moat, limiting direct competition from entrants who would need to invest heavily to overcome these barriers. The breadth of patents also facilitates strategic licensing to other manufacturers, generating non‑recurring revenues and reinforcing the company’s market position. A strong IP position is therefore a core pillar of long‑term value creation.
The partnership with CSL Seqirus and the joint venture in Japan, ARCALIS, provide access to established manufacturing facilities and distribution networks for both vaccines and therapeutics. These collaborations reduce capital intensity and accelerate time‑to‑market for new products, while also sharing commercial risks. The joint venture’s presence in Japan ensures that regulatory approval pathways in a large and lucrative market are more readily navigated. Together, these alliances create synergies that can accelerate revenue generation and broaden global reach.
While revenue has declined, the company’s cash balance of $237 million at year‑end, coupled with disciplined cost reductions, extends the runway into 2028 under current burn assumptions. This extended runway provides the financial flexibility to fund late‑stage clinical trials and scale‑up manufacturing without immediate dilution or debt. It also gives management breathing space to negotiate further collaborations or secure follow‑on funding. A solid cash position thus mitigates the risk of a funding crunch that could otherwise derail the pipeline.

Bear case

Regulatory hurdles have already stalled the KOSTAIVE COVID‑19 vaccine launch, and future changes to FDA vaccine requirements could further delay or impede approval. Such delays jeopardize the company’s ability to capitalize on the residual market demand for COVID‑19 boosters, eroding potential revenue. The uncertainty surrounding regulatory pathways introduces significant project risk that could materially affect valuation.
The company’s reliance on CSL Seqirus for vaccine commercialization exposes it to partner‑centric risks, including renegotiation of royalty terms or potential withdrawal of support. A shift in CSL’s strategic priorities could result in reduced licensing income and limited market access. This dependency on a single partner creates a single point of failure in the commercialization strategy.
Although cash reserves are currently adequate, the company’s burn rate remains high relative to revenue growth, and a failure to secure additional financing could shorten the runway. Future capital raises may require dilution, adversely impacting shareholder value. Sustained cash outflows could also limit the ability to fund late‑stage trials or scale‑up manufacturing, creating a funding bottleneck.
The clinical data for ARCT‑032 derive from a Phase 2 trial with only six participants, a short treatment period, and limited endpoints. This small, uncontrolled cohort cannot definitively demonstrate efficacy, leaving the product’s clinical value uncertain. The absence of robust, statistically significant efficacy data hampers regulatory approval prospects and market acceptance. Investors must be cautious given the high likelihood of a negative trial outcome.
Arcturus faces competition from larger mRNA developers such as Moderna and BioNTech, who possess more extensive resources, established commercial pipelines, and broader regulatory experience. These competitors can outpace Arcturus in scaling production, securing manufacturing capacity, and negotiating favorable licensing deals. The competitive advantage of a smaller biotech may erode market share and impede the company’s ability to secure lucrative partnerships.

Regulatory hurdles have already stalled the KOSTAIVE COVID‑19 vaccine launch, and future changes to FDA vaccine requirements could further delay or impede approval. Such delays jeopardize the company’s ability to capitalize on the residual market demand for COVID‑19 boosters, eroding potential revenue. The uncertainty surrounding regulatory pathways introduces significant project risk that could materially affect valuation.
The company’s reliance on CSL Seqirus for vaccine commercialization exposes it to partner‑centric risks, including renegotiation of royalty terms or potential withdrawal of support. A shift in CSL’s strategic priorities could result in reduced licensing income and limited market access. This dependency on a single partner creates a single point of failure in the commercialization strategy.
Although cash reserves are currently adequate, the company’s burn rate remains high relative to revenue growth, and a failure to secure additional financing could shorten the runway. Future capital raises may require dilution, adversely impacting shareholder value. Sustained cash outflows could also limit the ability to fund late‑stage trials or scale‑up manufacturing, creating a funding bottleneck.
The clinical data for ARCT‑032 derive from a Phase 2 trial with only six participants, a short treatment period, and limited endpoints. This small, uncontrolled cohort cannot definitively demonstrate efficacy, leaving the product’s clinical value uncertain. The absence of robust, statistically significant efficacy data hampers regulatory approval prospects and market acceptance. Investors must be cautious given the high likelihood of a negative trial outcome.
Arcturus faces competition from larger mRNA developers such as Moderna and BioNTech, who possess more extensive resources, established commercial pipelines, and broader regulatory experience. These competitors can outpace Arcturus in scaling production, securing manufacturing capacity, and negotiating favorable licensing deals. The competitive advantage of a smaller biotech may erode market share and impede the company’s ability to secure lucrative partnerships.

Counterparty Name Breakdown of Revenue (2025)

Lease Contractual Term Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools